The Gap Between Trial Patients and Real-World Care
A 62-year-old patient with newly diagnosed cervical cancer sits in your clinic. She has hypertension, limited transportation, and works hourly shifts without paid leave.
She is exactly the kind of patient you see every day.
She is also unlikely to be represented in the trial data guiding her treatment.
Clinical trials shape cancer care. They determine which treatments are tested, which guidelines are built, and which advances reach patients.
But in women’s cancers, especially those linked to human papillomavirus (HPV), there is still a gap between the patients enrolled in trials and the patients seen in everyday practice.
In gynecologic cancer research, that gap can be striking. One large study found that fewer than 1% of women with endometrial, ovarian, or cervical cancer were enrolled in a clinical trial, and most of those enrolled were white. This results in an evidence base that does not fully reflect the populations most affected by disease.
The Evidence Gap
Clinical trials are designed for control. Eligibility criteria help reduce variability and protect patient safety, but they also narrow who can participate.
Older adults.
Patients with comorbidities.
People treated outside major academic centers.
These groups are often excluded or underrepresented, even though they make up a large share of the real-world patient population. This leaves clinicians applying evidence to patients who do not resemble the study population.
Access Is the Barrier
For many patients, the issue is not willingness. It is access.
Referral pathways are inconsistent, and trial participation is rarely embedded into routine care. Instead, it depends on awareness, time, and proximity to research infrastructure. Patients are less likely to be offered trial participation if they are not connected to research-active institutions. Geography still matters, because trials remain concentrated in urban, well-resourced centers. And eligibility rules can exclude patients who might otherwise benefit.
These are systemic barriers, not individual ones. They shape who becomes part of the evidence base and who is left out of it.
What Participation Really Requires
Even when patients are eligible, participation requires more than consent.
Travel. Time away from work. Caregiving responsibilities. Financial strain. Language and cultural barriers.
These factors determine whether a patient can realistically enroll and stay enrolled.
Investigators see this play out in real time: eligible patients decline participation not because of lack of interest, but because participation is incompatible with daily life. Enrollment skews toward more resourced populations, and trial findings struggle to translate across settings.
Designing for Real-World Care
Improving access means rethinking how trials are designed and delivered.
- Decentralized and hybrid models can bring research closer to patients through local clinics and remote follow-up.
- Broader eligibility criteria can better reflect the populations who will ultimately receive treatment.
- Stronger referral networks can help clinicians connect patients to trials beyond their own institutions.
- Community engagement can build trust across diverse populations.
These approaches do not weaken science. They make it more relevant.
Why This Matters Now
In HPV-related cancers, the burden is highest in the populations least likely to be represented in trials. When those patients are missing from the evidence base, advances risk being least effective where they are needed most.
On Clinical Trials Day (June 20), it is easy to focus on innovation. But innovation only matters when it reaches the full spectrum of patients.
The challenge is no longer generating evidence. It is ensuring that evidence reflects real-world populations and translates into real-world care.
That means designing trials that are accessible, inclusive, and grounded in the settings where patients actually live and receive care.
Because progress is not defined by what we discover, but by who benefits.